Aperçu des produits pour anti-MAPKAP Kinase 2 (MAPKAPK2) Anticorps

Zebrafish Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2) interaction partners

1. a p38 MAPKAPK2 kinase cascade modulates the activity of F-actin at the yolk cell margin circumference allowing the gradual closure of the blastopore as epiboly progresses

Mouse (Murine) Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2) interaction partners

1. The importance of MK2 in driving proinflammatory cytokine production, its relevance to in vivo tumor proliferation and invasion.

2. MK2 promotes polarization of tumor-associated macrophages into protumorigenic, proangiogenic M2-like macrophages.

3. Phosphorylation of inhibitory PAS domain protein (IPAS) at Ser184 by MAPK-activated protein kinase 2 (MK2 or MAPKAPK2) enhances the proapoptotic function of IPAS.

4. MK2-mediated RIPK1 phosphorylation is an important molecular mechanism limiting the sensitivity of the cells to the cytotoxic effects of TNF.

5. p38MAPK/MK2 phosphorylation of RIPK1 is a crucial checkpoint for cell fate in inflammation and infection that determines the outcome of bacteria-host cell interaction.

6. MK2-mediated phosphorylation of RIPK1 serves as a checkpoint within the TNF signaling pathway that integrates cell survival and cytokine production.

7. this study shows that the loss of MK2 in mast cells decreases the IL-33-induced leukocyte recruitment and the resulting skin inflammation

8. MK2 signaling differentially regulated CCL3 and CCL4.

9. In silico analyses and experimental validation demonstrated that the kinase activity of p38(MAPK) determines signal amplitude, whereas phosphatase activity affects both signal amplitude and duration. p38(MAPK) and MK2 concentrations and responsiveness toward IL-1beta were quantitatively compared between hepatocytes and macrophages

10. MK2-activating peptide (MK2-AP) blocks the effects of anthrax lethal toxin on endothelial barriers in cultured cells and reduces pulmonary vascular leak in rats.

11. MK2 regulates postnatal arteriogenesis by controlling vascular recruitment of monocytes/macrophages in dual manner: regulation of endothelial MCP-1 expression in response to hemodynamic and inflammatory forces as well as MCP-1 dependent monocyte migration

12. these data suggest there is a sexual dimorphism in MK2 signaling of osteoclast progenitor cell subpopulations.

13. Loss of MK2 effectively blocks bone resorption and prevents the development of postmenopausal bone loss.

14. This study showed that cmpd28, a Mapkapk2/3 inhibitor, represents a potentially new approach to type 2 diabetes therapy.

15. Deficiency of MK2 prevents adverse remodelling and promotes endothelial healing of the arterial wall after injury.

16. high-fat diet-fed MK2-/- mice display decreased glucose tolerance and increased insulin resistance compared to controls. Decreased adipose tissue expression of GLUT4 might contribute to this phenotype.

17. Show a low dose of tumor necrosis factor (TNF) causes hyperacute mortality via an oxidative stress driven mechanism in MK2-deficient mice. In addition, MK2-deficient mice were found to be more sensitive to cecal ligation and puncture-induced sepsis.

18. a key role of MK2 and FasR in the regulation and limitation of the immune response in the CNS

19. These data suggest that MK2 is a key downstream effector of p38 that can modulate pemphigus vulgaris autoantibody pathogenicity.

20. Ube2j1 is phosphorylated in response to lipopolysaccharides in macrophages and contributes to MK2-dependent TNFalpha biosynthesis by an unknown mechanism.

Human Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2) interaction partners

1. These results reveal a novel mechanism by which miR-296-3p negatively regulated by nicotine directly targets MK2-induced Ras/Braf/Erk/Mek/c-Myc or PI3K/AKT/c-Myc signaling to stimulate its own expression and suppress NPC cell proliferation and metastasis.

2. Platelets drive a p38-MK2-RTN4-Bcl-xl pathway associated with the regulation of the endoplasmic reticulum and platelet phosphatidylserine exposure, modulating procoagulant phenotype.

3. Study found an elevated expression level of MK2 in serum specimens of patients with spinal cord injury. MiR-137 targets MK2 and inhibits its mediated inflammatory response and apoptosis after spinal cord injury.

4. The novel MK2 substrates have emerged in the DNA damage response, autophagy, and obesity, making MK2 a multifunctional kinase at the crossroads of stress response and cell death.

5. According to the information mentioned above, we now report the design and synthesis of some series of new urea derivatives that were then evaluated for their inhibitory activities against MAPKAPK2, TNF-a, and p38a

6. MK2 post-transcriptionally regulates TNF-alpha-induced ICAM-1 expression by altering the cytoplasmic localization of HuR in human lung microvascular endothelial cells.

7. MK2 overexpression is associated with primary liver tumors.

8. CEP131 is the key regulatory target of MK2 and 14-3-3 in centriolar satellite remodeling.

9. mTOR controls the senescence-associated secretory phenotype by differentially regulating the translation of the MK2 (also known as MAPKAPK2).

10. analysis of signaling cooperation between p38-MAPK/MAPKAP-2/Hsp27 and intracellular calcium release in AA-induced HBEC apoptosis

11. findings reveal MK2/MK3 as crucial stress-responsive kinases that promote autophagy through Beclin 1 S90 phosphorylation

12. Low pMK2 expression was found to correlate significantly with overall survival after induction plus chemoradiation therapy in head and neck squamous cell carcinoma patients.

13. The protein expression of both HMGB1 and MAPKAPK2 were increased in KLM1-R cells.

14. Data indicate the binding mode and molecular mechanism of action of MAPK-activated protein kinase-2 (MK2) and inhibitors.

15. Treatment with MK2 or p38 inhibitors blocked human papillomavirus genome amplification, identifying the p38/MK2 pathway as a key regulator of the human papillomavirus life cycle.

16. a key role of MK2 and FasR in the regulation and limitation of the immune response in the CNS

17. IscU is a new substrate of MK2 both in Drosophila cells and in human cells

18. MK2 mediates gemcitabine efficacy in pancreatic cancer cells that respond to the drug, suggesting that the p38/MK2 pathway represents a determinant of the efficacy by that gemcitabine counteracts pancreatic cancer.

19. MK2 plays a critical role in the development of apoptosis.

20. ATM and MAPKAP kinase 2 mediate radiation sensitivity in pancreatic cancer cells via phosphorylation of TRIM29.